List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Overview
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Companies Involved in Therapeutics Development
BLR Bio LLC
FibroGen Inc
ProMetic Life Sciences Inc
RXi Pharmaceuticals Corp
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Drug Profiles
BLR-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target SOD2 and CTGF for Radiation Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-DMD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-301D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamrevlumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Dormant Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Discontinued Products
Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF) - Product Development Milestones
Featured News & Press Releases
Mar 01, 2018: Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
Feb 16, 2018: Prometic Announces Publication of PBI-4050’s Novel Antifibrotic Mechanism of Action in American Journal of Pathology
Jan 29, 2018: Prometics PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
Dec 11, 2017: Prometic’s PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
Oct 25, 2017: Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis
Oct 20, 2017: Prometic Presents PBI-4050 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting
Sep 25, 2017: Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis
Sep 19, 2017: Prometic Reports Positive Clinical Data from Ongoing PBI-4050 Study in Alstrom Syndrome Patients
Sep 13, 2017: Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society International Congress 2017
Sep 05, 2017: FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
Aug 07, 2017: FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Jun 21, 2017: FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
Jun 21, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
Jun 12, 2017: New data presented by Prometic at ADA’s Scientific Sessions validates PBI-4050’s positive impact on kidneys in patients with diabetes and metabolic syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by BLR Bio LLC, H1 2018
Pipeline by FibroGen Inc, H1 2018
Pipeline by ProMetic Life Sciences Inc, H1 2018
Pipeline by RXi Pharmaceuticals Corp, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned
• BLR Bio LLC
• FibroGen Inc
• ProMetic Life Sciences Inc
• RXi Pharmaceuticals Corp